Clinical Trial Update: Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating an adenovirus-delivered VEGF therapy for vascular access in end-stage renal disease was terminated. The snippet does not report resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Adenovirus VEGF therapy (Ad-VEGF gene therapy (adenovirus-delivered VEGF))

Snippet

Sponsor: Ark Therapeutics Ltd | Conditions: End Stage Renal Disease | Phase 3 | Status: TERMINATED